EUVIMEDEUVIMED entdecken
Crossref

Deciphering the kidney hemodynamic effects of SGLT2 inhibition: translating insights from rats to humans in type 2 diabetes

Phoom Narongkiatikhun, Petter Bjornstad

Kidney International · 2024

DOI: 10.1016/j.kint.2024.06.018 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Kidney International, 2024. Verfasst von Phoom Narongkiatikhun und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, University of Washington School of Medicine, Seattle, Washington, USA; Division of Nephrology, Department of Internal Medicin…. Hauptthemen laut MEDLINE: Sodium-Glucose Transporter 2 Inhibitors, Diabetes Mellitus, Type 2, Diabetic Nephropathies, Hemodynamics. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 7 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The attenuation of glomerular hyperfiltration is posited to be a principal mechanism underlying the kidney protective effects of sodium-glucose cotransporter-2 (SGLT2) inhibitors in diabetic kidney disease. Notably, the impact of SGLT2 inhibitors on kidney hemodynamic function has been posited to vary between type 1 and type 2 diabetes. The study by Wada et al. documents that in an animal model of type 2 diabetes, SGLT2 inhibitors mitigate glomerular hyperfiltration predominantly through afferent arteriolar constriction, a process mediated by the adenosine/A1 receptor pathway. This observation is consistent with mechanisms identified in type 1 diabetes, arguing for similar methods in type 1 and 2 diabetes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Sodium-Glucose Transporter 2 InhibitorsDiabetes Mellitus, Type 2Diabetic NephropathiesHemodynamicsAnimalsHumansRatsGlomerular Filtration RateKidneySodium-Glucose Transporter 2ArteriolesTranslational Research, Biomedical

Substanzen

Sodium-Glucose Transporter 2 InhibitorsSodium-Glucose Transporter 2

Autor:innen und Institutionen

  • Department of Medicine, University of Washington School of Medicine, Seattle, Washington, USA; Division of Nephrology, Department of Internal Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand.
  • Department of Medicine, University of Washington School of Medicine, Seattle, Washington, USA. Electronic address: pettermb@uw.edu.

Zitieren

APA

Narongkiatikhun, P., & Bjornstad, P. (2024). Deciphering the kidney hemodynamic effects of SGLT2 inhibition: translating insights from rats to humans in type 2 diabetes. Kidney International. https://doi.org/10.1016/j.kint.2024.06.018

Vancouver

Narongkiatikhun P, Bjornstad P. Deciphering the kidney hemodynamic effects of SGLT2 inhibition: translating insights from rats to humans in type 2 diabetes. Kidney International. 2024. doi:10.1016/j.kint.2024.06.018

BibTeX
@article{Narongkiatikhun2024,
  author = {Narongkiatikhun, Phoom and Bjornstad, Petter},
  title = {Deciphering the kidney hemodynamic effects of SGLT2 inhibition: translating insights from rats to humans in type 2 diabetes},
  journal = {Kidney International},
  year = {2024},
  doi = {10.1016/j.kint.2024.06.018}
}
Kostenlos starten →